Davita Inc vs Kroger Co — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Kroger Co trades at $61.26 (market cap $36.27B). The key difference: Kroger Co is far larger — about 3.2× Davita Inc's market cap, and Kroger Co pays a 2.54% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Kroger Co for 108 Days on average.
| DVA | KR | |
|---|---|---|
Market Cap | $11.29B | $36.27B |
Volume | 582,204 | 8,301,523 |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $75.60 |
52-Week Low | $103.87 | $55.53 |
Typical Hold Time | 113 Days | 108 Days |
Enterprise Value | $24.01B | $57.69B |
Dividend Yield | — | 2.54% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Kroger (KR) trades at $59.25, up 1.44% with a bullish technical signal. The stock shows strong fundamentals with $147.12B revenue and $2.67B net income for 2025, supported by positive cash flow trends. Recent earnings beat expectations in two of the last three quarters, while analysts maintain a Moderate Buy consensus with a $70.62 price target. The company continues digital growth initiatives and maintains dividend payments.
Kroger presents a value opportunity with low P/S ratio (0.25) and consistent profitability, though near-term risks include integration challenges from acquisitions and softer sales guidance. The stock's current price near support at $58 offers potential upside to analyst targets, balanced by competitive pressures in the grocery sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →